바이오톡스텍

086040KOSDAQ

55.6 / 100

Reference Date: 2026-09-08

Financial Score16.0 / 40

News Sentiment20.6 / 25

Momentum9.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Rose 5.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

BioToxtek specializes in non-clinical CRO services, conducting toxicity and safety/efficacy evaluations using rodents and primates for pharmaceuticals, cell therapies, and chemicals. The company actively participates in new material development and is advancing the commercialization of therapeutic candidates like TB-4 and HX-1171 through technology licensing.

Number of Employees

241people

Average Salary

47.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

32.23Industry Average 15.000.0Point

2.1x industry avg (risky)

PBR

1.19Industry Average 1.204.0Point

In line with industry avg

ROE

-4.74Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

44.42Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲20.2% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲18.7% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -18.2% (improving, 3yr)

Detailed News Sentiment

4 totalPositive 4Neutral 0Negative 0Average Sentiment Score 82.5

Positive
바이오톡스텍, 자회사 첫 분기 흑자..."하반기 실적턴어라운드 기대"
바이오톡스텍의 자회사 키프라임리서치의 첫 분기 흑자 달성으로 상반기 매출과 수익성이 개선되어 긍정적 전망이 제기됨.
Positive
바이오톡스텍, 자회사 키프라임리서치 첫 분기 영업흑자
바이오톡스텍의 자회사 키프라임리서치의 첫 분기 흑자 달성으로 인해 회사의 외형 성장과 수익성 개선이 이루어졌다.
Positive
바이오톡스텍 상반기 매출 263억, 전년比 26%↑…"수익성 반등"
바이오톡스텍의 상반기 매출이 전년 대비 26% 증가하며 흑자 전환을 달성하고, 수주잔고 확대와 자회사의 성과로 수익성 개선이 기대된다.

Detailed Momentum

52-week position3.0Point

52w lower range (20%)

Current 2,385Won52-week high 3,92552-week low 1,983

1-month return4.0Point

1m +5.76% (slight rise)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

9 totalPositive 0Neutral 9Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-09-07
Neutral주식등의대량보유상황보고서(일반)2026-09-07
Neutral주식등의대량보유상황보고서(일반)2026-09-01
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-09-01
Neutral주식등의대량보유상황보고서(일반)2026-08-31